Auxilium Pharmaceuticals Inc

Auxilium Pharmaceuticals — Investor Presentation (March 2010)

49 slides from Auxilium Pharmaceuticals's investor presentation, Mar 4, 2010

  1. Slide 1: March 2010

    March 2010 Exhibit 99.1 (NASDAQ: AUXL)

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement We will make various remarks during this presentation that constitute “forward-looking statements” for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995, including statements regarding the pricing, time to market, size of market,

  3. Slide 3: Focused on Sustainable Long-term Growth

    Focused on Sustainable Long-term Growth Testim XIAFLEX Dupuytren’s XIAFLEX Peyronie’s XIAFLEX New Indications XIAFLEX New Territories

  4. Slide 4: Pipeline Continues to Advance

    Pipeline Continues to Advance TESTIM ® GEL XIAFLEX™ XIAFLEX™ XIAFLEX™ Transmucosal Film AA4010 Transmucosal Film Transmucosal Film Hormone & Urology Note: Seeking partners for Transmucosal film product candidates PRODUCT LATE RESEARCH PRE-CLINICAL PHASE I PHASE II PHASE III MARKET Hypogonadism Dupuy

  5. Slide 5: cease an Jetset

    cease an Jetset fxonty hed Paton collagenase clostridium histolyticum x for for intralesional use Sterile Dituent ‘Attention: Dispense the et Medication Guide to each’ > SS Innovations for Life™

  6. Slide 6: XIAFLEX – Unique, Late-Stage, Blockbuster Opportunity

    XIAFLEX – Unique, Late-Stage, Blockbuster Opportunity Potential to be the only effective non-surgical treatment for two high unmet needs: Approved on February 2, 2010 for Dupuytren’s Contracture in U.S. Promising phase IIb results in Peyronie’s disease Well-characterized mode of action State of the

  7. Slide 7: Dupuytren's Contracture is Debilitating for Patients

    Dupuytren’s Contracture is Debilitating for Patients Excessive collagen deposition in fascia of hand Nodules represent early, active form Cords develop over time, are palpable, and result in contractures Quality of life and daily activities can be significantly affected Surgery may be reserved for a

  8. Slide 8: Current Treatment Options Require Invasive Surgery or Are Unapproved and Ineffective

    Current Treatment Options Require Invasive Surgery with Significant Recuperation or Are Unapproved and Ineffective Surgery Non-surgical options Splinting Physical therapy Corticosteroids Needle fasciotomy/ aponeurotomy Amputation

  9. Slide 9: XIAFLEX Offers an Improved Mechanism of Action

    XIAFLEX Offers an Improved Mechanism of Action Clostridial collagenase is faster and more potent than human collagenase – Activity of XIAFLEX further enhanced by optimizing the ratio of collagenases in the product End products Fast cleavage Human collagenase Human collagenase (MMP) (MMP) Slow cleava

  10. Slide 10: We Believe XIAFLEX Label Is a Positive for Launch

    We Believe XIAFLEX Label Is a Positive for Launch XIAFLEX is indicated for the treatment of adult patients with Dupuytren’s contracture with a palpable cord. Indicated for treatment of both MP and PIP joints with no minimum or maximum angles To be injected by a healthcare provider experienced in inj

  11. Slide 11: Innovations for tite”

    40.0% 9% Zz” ca Innovations for tite” 72% 76.7% UoIsue}Xq [WON Jo 69- 6050 BulAeluoy squloe 6.8% i” 64.0% UoIsue}Xq [EWUON Jo 9- 6050 Bu 4 |

  12. Slide 12: XIAFLEX Was Well-Tolerated in Phase III Studies

    XIAFLEX Was Well-Tolerated in Phase III Studies Most treatment related adverse events were mild or moderate in intensity and resolved without intervention within a median of 9 days across studies Severe Adverse Events possibly related to treatment were limited in number (10 in total; 0.39% of >2600

  13. Slide 13: XIAFLEX is a Potential, First-line Nonsurgical Option for Dupuytren's Contracture

    XIAFLEX is a Potential, First-line Nonsurgical Option for Patients with Dupuytren’s Contracture Efficacy should compare favorably to surgery Primary endpoint of 5° for both MP and PIP joints reached with statistical significance in multiple studies Secondary endpoints support commercial uptake Early

  14. Slide 14: XIAFLEX Offers a Nonsurgical Treatment for Dupuytren's Contracture

    XIAFLEX Offers a Nonsurgical Treatment for Dupuytren’s Contracture

  15. Slide 15: XIAFLEX I.P. Position for Dupuytren's Contracture

    XIAFLEX I.P. Position for Dupuytren’s Contracture U.S. Orphan Drug granted on May 23, 1996 provides exclusivity for 7 years post-approval Market Exclusivity expected in EU for 10 years post-approval Data protection granted for 8 years Method of Use Patent in U.S. through 2014 Use Patent in France, U

  16. Slide 16: XIAFLEX Supply Chain

    XIAFLEX Supply Chain API produced in Horsham, PA 2 ° - 8 ° C storage expected at launch Annual capacity at current yield should be sufficient for several years of global launch expectations 1 manufacturing train in use and validated; capacity to expand for future demand Fill and Lyophilization: Holl

  17. Slide 17: Dupuytren's Contracture – an Unmet Medical Need

    Dupuytren’s Contracture –an Unmet Medical Need NEJM 2009 ² Hueston 1963 ³ Skoog 1948 Mikkelsen 1976 Tubiana 2006 Disease prevalence (pits, nodules, or cords) is estimated at 3%-6% of adult Caucasian population, or 13.5 to 27 Million, in U.S. and EU, but occurs in all populations Higher prevalence in

  18. Slide 18: Extensive Market Research Performed with Dupuytren's Surgeons

    Extensive Market Research Performed with Dupuytren’s Surgeons Multiple prevalence data sets proved to be highly variable in numbers of patients Two rounds of quantitative primary research have been commissioned by Auxilium on XIAFLEX for Dupuytren’s contracture A combined 571 Orthopedic Surgeons hav

  19. Slide 19: Annually, >240,000 Dupuytren's Candidates Could Exist between U.S. & EU

    Annually, >240,000 Dupuytren’s Candidates Could Exist between U.S. & EU Source: 2006 Auxilium research and analysis Dupuytren’s Disease (pits, nodules or cords) Prevalence: 3-6% of Adult Caucasian Population ~13,500,000 to 27,000,000

  20. Slide 20: XIAFLEX Commercial Strategy is Tailored to Customer Needs

    XIAFLEX Commercial Strategy is Tailored to Customer Needs ~ 7,000 target physicians Hand surgeons, plastic surgeons, orthopedic surgeons, general surgeons, rheumatologists Limited distribution network Buy and bill vs. specialty pharmacy ~ 100 field representatives sales reps, sales managers, and rei

  21. Slide 21: XIAFLEX Price of $3,250 Determined Following Detailed Assessment

    XIAFLEX Price of $3,250 Determined Following Detailed Assessment Of Key Stakeholder Drivers DRIVERS: Financial risk vs. return Could provide reimbursement on par with surgery Shorter procedure to allow larger volumes to be treated and free up time for other procedures DRIVERS: Surgery cost vs. value

  22. Slide 22: Reimbursement Uncertainty May Create Headwinds

    Reimbursement Uncertainty May Create Headwinds Miscellaneous J and CPT codes will be used Establishment of new product specific J code expected for 2011 and procedure codes (CPT) expected in 2012 Accounts naive to the reimbursement process will need customized support Claims processing at payer leve

  23. Slide 23: XIAFLEX Training Options and Resources

    XIAFLEX Training Options and Resources ~20 minute training video and product information on- line at www.XIAFLEX.com 1-877-XIAFLEX for training and training information Reimbursement Helpline Patient assistance program Co-pay foundation

  24. Slide 24: XIAFLEX REMS In Line With Our Goal Of Ensuring Appropriate Administration

    XIAFLEX REMS In Line With Our Goal Of Ensuring Appropriate Administration Recognize potential and identified risks Potential: Injection related bleeding due to coagulation disorder, allergic reactions Identified: localized reactions and tendon ruptures Creation and implementation of strategies to mi

  25. Slide 25: Sustainable Blockbuster Market for Dupuytren's Contracture Anticipated

    Sustainable Blockbuster Market for Dupuytren’s Contracture Anticipated High disease prevalence Based on literature, ~ 13.5M to 27M patients in U.S. and EU have a Dupuytren’s pit, nodule or cord, however only ~ 1M patients annually seeking treatment in U.S. and EU Sustainable patient pool New patient

  26. Slide 26: Key Objectives for U.S. XIAFLEX Launch in 2010

    Key Objectives for U.S. XIAFLEX Launch in 2010 Begin supplying our distribution partners with XIAFLEX in the week of March 1; shipping to trained physician’s enrolled in XIAFLEX Xperience beginning week of March 8 Get targeted physicians through training and into distribution database Achieve high a

  27. Slide 27: Peyronie's Disease is a Devastating Disorder

    Peyronie’s Disease is a Devastating Disorder Smith BH. Am J Clin Pathol . 1966;45:670-678. Somers KD, Dawson DM. J Urol . 1997;157:311-315. Scarring phenomenon affecting the tunica albuginea Plaques show excessive collagen deposition Potential Symptoms Pain with erection, penile curvature/ deviation

  28. Slide 28: Peyronie's Disease - an Unmet Medical Need

    Peyronie’s Disease - an Unmet Medical Need Schwarzer U, The prevalence of Peyronie’s disease: Results of a large survey. BJU Int 2001;88:727-30; Mulhall et al: J Urology 2004:171: 2350 - 2353;Rhoden et al: Int J. Impot Res 2001 :13 : 291 - 293; La Pera et al : EUR Urology 2001: 40 :525 - 530. Smith

  29. Slide 29: Peyronie's Phase IIb Study Designed To Assess Safety And Efficacy

    Peyronie’s Phase IIb Study Designed To Assess The Safety And Efficacy With XIAFLEX Study design: XIAFLEX was administered two times a week every six weeks for up to three treatment cycles (2 x 3) 145 patients at 12 U.S. sites Patients must have been able to maintain a rigid erection with a penile co

  30. Slide 30: Peyronie's Phase IIb Trial Utilized a Novel Patient Reported Outcome

    Peyronie’s Phase IIb Trial Utilized a Novel Patient Reported Outcome (PRO) Study was designed to validate Auxilium’s proprietary Peyronie’s Patient Reported Outcome (PRO) questionnaire. PRO measured four domains of patients’ sexual quality of life, over a 36 week period: penile pain Peyronie’s disea

  31. Slide 31: Promising Phase IIb Data in Peyronie's Disease

    Promising Phase IIb Data in Peyronie’s Disease Overall – Significant XIAFLEX effect Reduction of penile curvature Improvement in Peyronie’s Disease Bother (PRO Domain) XIAFLEX With Modeling Significant effect in both penile curvature and Peyronie’s disease bother endpoints XIAFLEX Without Modeling N

  32. Slide 32: Mean Penile Curvature Improved Significantly

    At 36 weeks, Mean Penile Curvature Improved Significantly

  33. Slide 33: Overall Mean Score Change with Peyronie's Disease Bother Improved Significantly

    At 36 weeks, Overall Mean Score Change with Peyronie’s Disease Bother Improved Significantly

  34. Slide 34: Anticipated Next Steps for Peyronie's disease

    Anticipated Next Steps for Peyronie’s disease End of Phase II meeting with FDA expected in 2Q10 to discuss: Validation of PRO Phase III trial design Anticipate commencing U.S. Phase III study in 2H10

  35. Slide 35: Extensive Market Research Performed with Peyronie's Surgeons

    Extensive Market Research Performed with Peyronie’s Surgeons Two rounds of quantitative primary research have been commissioned by Auxilium on XIAFLEX for Peyronie’s disease A combined 575 Urologists have been interviewed to estimate market size (415 in U.S.; 160 in Europe) and 383 have given feedba

  36. Slide 36: Annually, >210,000 Peyronie's Candidates May Exist in U.S. and Europe

    Annually , > 210,000 Peyronie ’ s Candidates May Exist in U.S. and Europe Source: 2006 Auxilium research and analysis

  37. Slide 37: XIAFLEX I.P. Position for Peyronie's Disease

    XIAFLEX I.P. Position for Peyronie’s Disease U.S. Orphan Drug granted on March 12, 1996 provides exclusivity for 7 years post-approval Market Exclusivity in EU could be extended to 11 years on approval of additional indication Method of Use Patent in U.S. through 2019 Use Patent Granted in France, U

  38. Slide 38: Strategic Partnership with Pfizer for XIAFLEX in EU

    Strategic Partnership with Pfizer for XIAFLEX in EU Strong working relationship with goal to obtain EMEA approval Auxilium is primarily responsible for the global development of XIAFLEX, including all clinical & commercial manufacturing and supply. Pfizer is primarily responsible for: European terri

  39. Slide 39: Testim 1% Testosterone Gel

    Testim ® 1% Testosterone Gel

  40. Slide 40: Testim Maintains Double-Digit Growth in Testosterone Replacement Therapy Market

    Testim ® Maintains Double-Digit Growth in Testosterone Replacement Therapy Market *Mulligan T. et al. Int J. Clin Pract Proprietary, topical 1% testosterone gel Once-a-day application Favorable clinical and commercial profile Recent study indicates 39% of U.S. males over 45 yrs are hypogonadal* We e

  41. Slide 41: 447% +30%

    447% +30%

  42. Slide 42: Gels Continue to Drive Significant Growth in TRT Marketplace

    Gels Continue to Drive Significant Growth in TRT Marketplace Source: IMS data

  43. Slide 43: Testim Quarterly Net Revenues and Scripts Continuing Track Record of Consistent Revenue Growth

    Testim® Quarterly Net Revenues and Scripts Continuing Track Record of Consistent Revenue Growth ($ in millions) 4Q09 Net Testim Revenues Y/Y Growth: +24.4% 4Q09 TRX Y/Y Growth: +13.2% Source: Auxilium and IMS data $42.8M $68.9M $95.7M $125.2M $151.9M

  44. Slide 44: Testim Patent Coverage

    Testim Patent Coverage *Note: The referenced Testim patents are owned by CPEX Pharmaceuticals, Inc. U.S. U.S. Patent # 7,320,968* covering method of use claims for Testim issued January 22, 2008; expires 2025 6 additional U.S. Patents (# 7,608,605 through 610*) covering method of use claims for Test

  45. Slide 45: FDA Has Granted Our Citizen's Petition In Part And Denied It In Part

    FDA Has Granted Our Citizen's Petition In Part And Denied It In Part Auxilium’s Citizen’s Petition was filed in February 2009 and FDA response was received in August 2009. FDA has agreed with some of the statements we made in our Citizen's Petition regarding the testing required for generic versions

  46. Slide 46: 2009 Financial Results and 2010 Guidance

    Testim Revenues $47.2 $160.4 $185-195 R&D Expense* $11.4 $51.4 $50-60 SG&A Expense* $38.7 $129.2 $160-170 Net Loss ($11.9) ($53.5) N/A Stock – Based Comp Expense (* included) $4.4 $17.9 $22-25 Cash & Cash Equivalents $182.0 2009 Financial Results and 2010 Guidance ($ Millions) Q4 ’09 2009 Guidance C

  47. Slide 47: Strategic Priorities in 2010

    Strategic Priorities in 2010 Execute the launch in the U.S. for XIAFLEX in Dupuytren’s contracture; Support Pfizer in the ongoing regulatory review of the EU Dupuytren’s submission and prepare for their eventual launch; Commence phase III for XIAFLEX in Peyronie’s disease, assuming a successful End-

  48. Slide 48: Focused on Sustainable Long-term Growth

    Focused on Sustainable Long-term Growth Testim XIAFLEX Dupuytren’s XIAFLEX Peyronie’s XIAFLEX New Indications XIAFLEX New Territories

  49. Slide 49: Auxilium Management Contact

    Auxilium Management Contact James E. Fickenscher/CFO Auxilium Pharmaceuticals, Inc. (484) 321-5900 [email protected] William Q. Sargent Jr./ VP IR Auxilium Pharmaceuticals, Inc. (484) 321-5900 [email protected] March 2010 (NASDAQ: AUXL)

Auxilium Pharmaceuticals — Investor Presentation (March 2010) on 6ix